KM Research Hub
← 返回论文库
待处理 入排:符合 图源:待检查 入排置信度 0.96

Nivolumab Plus Ipilimumab as First-Line Treatment for Patients With Metastatic Non-Small Cell Lung Cancer: Final, 7.5-Year Outcomes From CheckMate 227.

Martin Reck, Tudor-Eliade Ciuleanu, Adam Pluzanski, Jong-Seok Lee, Mauricio Mahave, Clarisse Audigier-Valette, Reyes Bernabe Caro, Suresh S Ramalingam, Luis G Paz-Ares, Hossein Borghaei, Kenneth J O'Byrne, Makoto Nishio, Solange Peters, Laszlo Urban, Lorena Lupinacci, Randeep Sangha, Jacobus A Burgers, Samreen Ahmed, Matthew D Hellmann, Adam J Schoenfeld, Lily Wang, Stephen McCraith, Yu-Han Hung, Nathanial Eddy, Virginia Ip, Julie R Brahmer

J Thorac Oncol 106258

PMID43057628
PMCID-
DOI10.1016/j.jtho.2026.106258
发表日期2026-11-19
入排依据:明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
摘要

摘要

INTRODUCTION: The phase 3 CheckMate 227 Part 1 study (NCT02477826) demonstrated survival benefit with first-line nivolumab plus ipilimumab versus chemotherapy in patients with metastatic non-small cell lung cancer (NSCLC). Here, we report final, 7.5-year efficacy and safety results. METHODS: Adults with stage IV/recurrent NSCLC and no sensitizing EGFR/ALK mutations were stratified by programmed death ligand 1 (PD-L1) ≥1% (n = 1189) or <1% (n = 550) and randomized to nivolumab plus ipilimumab, nivolumab alone (PD-L1 ≥1% only), nivolumab plus chemotherapy (PD-L1 <1% only), or chemotherapy alone. Assessments included overall survival (OS), duration of response, and safety. RESULTS: At a minimum follow-up of 91.9 months, nivolumab plus ipilimumab continued to demonstrate long-term OS benefit versus chemotherapy in patients with tumor PD-L1 ≥1% (7-year OS rates, 19% versus 10%; hazard ratio [HR], 0.78; 95% CI: 0.67-0.91) or tumor PD-L1 <1% (7-year OS rates, 14% versus 4%; HR, 0.64; 95% CI: 0.51-0.79). Rates of ongoing response at 7 years were higher with nivolumab plus ipilimumab than chemotherapy among responders with tumor PD-L1 ≥1% (25% versus 3%) or tumor PD-L1 <1% (20% versus 3%). Clinical benefit with nivolumab plus ipilimumab was observed across most patient subgroups, including those with squamous or non-squamous NSCLC or selected oncogenic driver mutations. No new safety signals were observed. CONCLUSIONS: This final analysis from CheckMate 227 confirms that nivolumab plus ipilimumab confers long-term, durable clinical benefit versus chemotherapy in patients with metastatic NSCLC across both the tumor PD-L1 ≥1% and PD-L1 <1% populations, reinforcing nivolumab plus ipilimumab as a first-line treatment option for these patients.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。